
- Volume 0 0
ProQuad [Measles, Mumps, Rubella, and Varicella (Oka/Merck) Virus Vaccine Live]
Merck & Co Inc (Whitehouse Station, NJ) recently received FDA approval for the combination vaccine ProQuad for simultaneous vaccination against measles, mumps, rubella (German measles), and varicella (chickenpox) in children 12 months to 12 years of age. The product also may be used in this patient group if a second dose of measles, mumps, and rubella vaccine is to be administered. Patients should receive a 0.5-mL single dose of ProQuad subcutaneously. At least 1 month should elapse between a dose of a measles-containing vaccine and a dose of ProQuad. If a second dose of varicella-containing vaccine is required, at least 3 months should elapse. For more information, visit
Articles in this issue
almost 20 years ago
CAN YOU READ THESE Rxs?almost 20 years ago
Bar Coding Thwarts Illegitimate Drug Usealmost 20 years ago
COMPREHENSIVE CARE CLINIC: DIABETES: Diabetes-related Stress and Depressionalmost 20 years ago
Hypertension Counseling Requires a Multifactorial Approachalmost 20 years ago
COMPOUNDING HOTLINEalmost 20 years ago
Pharmacy Law: Duty to Warn Waived When Patient Refuses Counselingalmost 20 years ago
EnterpriseRx Pharmacy Management Systemalmost 20 years ago
Hospital Installs Automated Medication Cabinetsalmost 20 years ago
"Smartphones" Help with Clinical Trial Informationalmost 20 years ago
HIT Needs Medicare's LeadershipNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.